Trial Profile

An exploratory study to assess the efficacy and safety of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selexipag (Primary)
Indications Pulmonary hypertension
Focus Therapeutic Use
Sponsors Actelion Pharmaceuticals; Nippon Shinyaku

Most Recent Events

03 Sep 2020 Primary endpoint (Change from baseline of pulmonary vascular resistance (PVR)) has not been met, as per Results published in the Circulation Journal
03 Sep 2020 Results published in the Circulation Journal
16 Jun 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com